Dark Forest Capital Management LP Has $832,000 Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Dark Forest Capital Management LP decreased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 39.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,319 shares of the biopharmaceutical company's stock after selling 29,225 shares during the quarter. Dark Forest Capital Management LP's holdings in ACADIA Pharmaceuticals were worth $832,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in ACADIA Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after buying an additional 104,444 shares in the last quarter. First Trust Advisors LP grew its stake in shares of ACADIA Pharmaceuticals by 27.0% in the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock valued at $49,547,000 after acquiring an additional 574,251 shares in the last quarter. SG Americas Securities LLC increased its position in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after acquiring an additional 1,966,607 shares during the period. Norges Bank acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter worth about $25,555,000. Finally, Renaissance Technologies LLC boosted its holdings in ACADIA Pharmaceuticals by 204.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock valued at $22,507,000 after purchasing an additional 823,333 shares during the period. Institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Stock Up 0.3 %

Shares of ACAD stock traded up $0.04 during trading hours on Wednesday, hitting $14.47. 468,115 shares of the company's stock traded hands, compared to its average volume of 1,842,891. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $20.68. The stock has a market cap of $2.41 billion, a PE ratio of 18.52 and a beta of 0.54. The stock's 50 day simple moving average is $16.42 and its 200 day simple moving average is $16.93.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 2,708 shares of the company's stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the sale, the executive vice president now owns 59,456 shares of the company's stock, valued at approximately $881,137.92. This represents a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,169 shares of company stock valued at $242,686. 28.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Guggenheim cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a "hold" rating and a $22.00 target price for the company. Morgan Stanley restated an "equal weight" rating and issued a $20.00 price target on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Finally, UBS Group cut their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research report on Monday. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.87.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.